In the Latest in a Series of Wins, Finland Airports Select Implant Sciences' QS-B220

Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 58 of its QS-B220 desktop explosives trace detectors to Finnish Airports. The systems are scheduled to be deployed within the next several months.

"The QS-B220 is the only fully developed, globally certified, and deployed non-rad ETD on the market. Customers all across Europe are actively responding to our superior performance and value proposition, as we continue to win tender after tender," stated Dr. Darryl Jones , Implant Sciences' Vice President of Sales and Marketing. "We have found that, when we go head to head with our competitors in these EU airport trials, we have been selected as the optimal vendor nearly every time. Clients are seeing that not all non-rad ETD units perform equally, and we are confident that our market penetration will continue throughout the EU."

"Though not necessarily the lowest-priced unit, our unit's outstanding performance in the operational trial at the airport led us to being selected over the competition," added Dr. Bill McGann , Implant Sciences' CEO. "The QS-B220 is a top-performing unit in the ETD industry. For airports, balancing security with high-throughput is of the utmost importance, and we believe that our unit consistently delivers."

About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

Source: Implant Sciences Corporation
Date: Jun 30, 2015